Axsome Therapeutics (AXSM) Interest & Investment Income (2015 - 2026)

Axsome Therapeutics has disclosed Interest & Investment Income across 12 years of filings, most recently posting -$1.2 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at -$1.2 million, up 51.25% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.3 million (up 32.92% YoY), and the FY2025 annual result was -$6.6 million, changed 0.18% from the prior year.
• Interest & Investment Income came in at -$1.2 million for Q1 2026 at Axsome Therapeutics, down from -$1.2 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of -$702000.0 in Q4 2023 to a low of -$2.7 million in Q2 2023.
• The 5-year median for Interest & Investment Income is -$1.3 million (2022), against an average of -$1.7 million.
• Across the five-year window, Interest & Investment Income surged 68.6% in 2023 and tumbled 214.81% in 2024, its largest moves.
• Axsome Therapeutics' Interest & Investment Income stood at -$1.3 million in 2022, then surged by 46.94% to -$702000.0 in 2023, then sank by 214.81% to -$2.2 million in 2024, then jumped by 46.97% to -$1.2 million in 2025, then retreated by 1.11% to -$1.2 million in 2026.
• The last three Interest & Investment Income figures came in at -$1.2 million (Q1 2026), -$1.2 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.